news
Donanemab Alzheimer's drug starts treating patients in Spain
Eli Lilly's Alzheimer's drug, donanemab, has begun treating its first patients in Spain at Madrid's Fundación Jiménez Díaz University Hospital. Patients receive intravenous infusions every four weeks for 12 to 18 months, targeting amyloid plaques in the brain. This rollout follows its European Medicines Agency review and offers a new option for early-stage Alzheimer's.
Eli Lilly's Alzheimer's drug, donanemab, has begun treating its first patients in Spain at Madrid's Fundación Jiménez Díaz University Hospital. Patients receive intravenous infusions every four weeks for 12 to 18 months, targeting amyloid plaques in the brain. This rollout follows its European Medicines Agency review and offers a new option for early-stage Alzheimer's.
The architecture take
So, donanemab is officially out there, treating actual people with early-stage Alzheimer's. This isn't some experimental trial anymore; it's a real-world treatment, given as a monthly infusion for over a year. The drug works by clearing amyloid plaques, which are a hallmark of the disease, and studies showed it can slow cognitive decline by about a third for those with early symptoms. The catch? You need to catch Alzheimer's early, and the treatment carries risks like brain swelling or microhemorrhages, so regular MRI monitoring is a must. This isn't a cure, but it's a huge step forward in managing a brain state that used to be a one-way street. I'm watching to see how this impacts diagnostic rates and early screening programs, because access to this kind of intervention depends entirely on early detection.